This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinicaltrials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinicaltrial design that have historically led to trial failure?
Josh Sackman, president and co-founder of AppliedVR, and Web Sun, president and co-founder of Komodo Health, relay how their newly formed collaboration reshapes the clinicaltrial process by using data, helping to cut costs and allowing for evaluation of broader patient populations. .
The clinicaltrials landscape is evolving more rapidly than ever before. Meanwhile, decentralisation and the BigData revolution are transforming the way researchers run clinicaltrials, and previously untapped geographies are emerging as new hubs for future research.
AI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘BigData’ and data scientists within their R&D teams. Learn about the new breakthroughs within clinicaltrials and the treatment of disease. Who Should Attend?
Komodo’s Healthcare Map was previously used to help diagnose rare metastatic renal cell carcinoma patients, and Janssen Research & Development uses Komodo’s software for clinicaltrials for various therapeutic areas, including rare diseases. CZI has also partnered with large data collection agencies before.
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through businessdevelopment activities. billion ($3.65 billion USD), became the first shingles vaccine to receive FDA approval in 2017. billion ($2.85
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content